BridgeBio Pharma, Inc. (BBIO)
Automate Your Wheel Strategy on BBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including BBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BBIO
- Rev/Share 1.8569
- Book/Share -10.0922
- PB -6.693
- Debt/Equity -0.9621
- CurrentRatio 3.8753
- ROIC -0.775
- MktCap 13086868190.0
- FreeCF/Share -3.1242
- PFCF -21.9869
- PE -16.231
- Debt/Assets 1.863
- DivYield 0
- ROE 0.4663
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BBIO | Barclays | -- | Overweight | -- | $157 | Jan. 28, 2026 |
| Initiation | BBIO | Morgan Stanley | -- | Overweight | -- | $96 | Jan. 6, 2026 |
| Initiation | BBIO | Bernstein | -- | Outperform | -- | $94 | Dec. 11, 2025 |
| Resumed | BBIO | Raymond James | -- | Outperform | -- | $56 | July 30, 2025 |
| Initiation | BBIO | Truist | -- | Buy | -- | $66 | July 21, 2025 |
| Initiation | BBIO | Jefferies | -- | Buy | -- | $70 | July 14, 2025 |
| Upgrade | BBIO | Oppenheimer | Perform | Outperform | -- | $60 | July 9, 2025 |
| Initiation | BBIO | Wolfe Research | -- | Outperform | -- | $49 | June 17, 2025 |
| Initiation | BBIO | Redburn Atlantic | -- | Buy | -- | $50 | March 31, 2025 |
| Initiation | BBIO | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
News
BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Negative
BridgeBio Pharma (BBIO) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $0.96 per share a year ago.
Read More
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients on November 22, 2024 - Acoramidis was approved as BEYONTTRA™ in the EU on February 10, 2025, achieving a $75 million milestone payment and ongoing royalties in a tiered structure beginning in the low-thirties percent on sales in the EU - Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of …
Read More
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, on February 20, 2025. As part of the announcement, the Company will also share updates on Attruby's commercialization progress and its late-stage clinical pipeline.
Read More
About BridgeBio Pharma, Inc. (BBIO)
- IPO Date 2019-06-27
- Website https://www.bridgebio.com
- Industry Biotechnology
- CEO Neil Kumar
- Employees 725